Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome.
暂无分享,去创建一个
Ming-Yang Chang | Chih-Hsiang Chang | Ya-Chung Tian | Ming-Yang Chang | Chih-Wei Yang | Ya-Chung Tian | Yung-Chang Chen | C. Hung | Chih-Wei Yang | Cheng-Chieh Hung | Ji-Tseng Fang | Yung-Chang Chen | Ji-Tseng Fang | Chih-Hsiang Chang | Jui-Hsiang Lin | Kun-Hua Tu | Chun-Chen Yu | K. Tu | Chun‐Chen Yu | Jui-Hsiang Lin
[1] M. Kiernan,et al. Guillain-Barré syndrome: An update , 2009, Journal of Clinical Neuroscience.
[2] J. Schessl,et al. Clinical Presentation and Course of Childhood Guillain-Barré Syndrome: A Prospective Multicentre Study , 2007, Neuropediatrics.
[3] M. Ogino,et al. Tryptophan‐immobilized Column‐based Immunoadsorption as the Choice Method for Plasmapheresis in Guillain–Barré Syndrome , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[4] A. Kaplan. Therapeutic plasma exchange: core curriculum 2008. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] Cheng-Hsien Lu,et al. Long‐term prognosis for Guillain‐Barré syndrome: Evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis , 2003, Journal of clinical apheresis.
[6] S. Hsieh,et al. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[7] D. Cornblath,et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders , 2011, Neurology.
[8] M. Mori,et al. Haemophilus influenzae infection and Guillain-Barré syndrome. , 2000, Brain : a journal of neurology.
[9] W. Szczeklik,et al. Complications in patients treated with plasmapheresis in the intensive care unit. , 2013, Anaesthesiology intensive therapy.
[10] P. Doorn. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) , 2013 .
[11] R. Hughes,et al. CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.
[12] D. Kiprov,et al. Adverse reactions associated with mobile therapeutic apheresis:Analysis of 17,940 procedures , 2001, Journal of clinical apheresis.
[13] S. Vesely,et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome , 2000 .
[14] W. Hacke,et al. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .
[15] K. Hirata,et al. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption , 1998, Journal of the Neurological Sciences.
[16] B. Colls. Guillain−Barré syndrome and hyponatraemia , 2003, Internal medicine journal.
[17] R. Weinstein,et al. Complications of therapeutic plasma exchange: A recent assessment , 1994, Journal of clinical apheresis.
[18] P. Schmitz,et al. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.
[19] H. Hartung,et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.
[20] R. Weinstein,et al. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis , 2007, Journal of clinical apheresis.
[21] V. Bril,et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome , 1996, Neurology.
[22] M. Musthafa,et al. Guillain-Barré syndrome and SIADH , 2011, Neurology.
[23] M. Versino,et al. Guillain-Barré syndrome , 2006, Neurological Sciences.
[24] D. Annane,et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. , 2007, Brain : a journal of neurology.
[25] B. Jacobs,et al. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome , 2008, The Lancet Neurology.
[26] A. Soysal,et al. Clinico‐electrophysiological findings and prognosis of Guillain‐Barré syndrome – 10 years’ experience , 2011, Acta neurologica Scandinavica.
[27] A. Pithadia,et al. Guillain-Barré syndrome (GBS) , 2010, Pharmacological reports : PR.
[28] H. Chiu,et al. Experience of double filtration plasmapheresis in the treatment of Guillain‐Barré syndrome , 1999, Journal of clinical apheresis.
[29] E. Steyerberg,et al. A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.
[30] A. Uncini,et al. Outcome and its predictors in Guillain–Barré syndrome , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[31] Hester F. Lingsma,et al. Early recognition of poor prognosis in Guillain-Barré syndrome , 2011, Neurology.
[32] C.-H. Lu,et al. Guillain–Barré syndrome in southern Taiwan: clinical features, prognostic factors and therapeutic outcomes , 2003, European journal of neurology.
[33] A. Chiò,et al. Guillain-Barré syndrome , 2003, Neurology.
[34] O. Gungor,et al. Plasmapheresis therapy in renal transplant patients: five-year experience. , 2011, Transplantation proceedings.
[35] R. Porcher,et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study , 2006, The Lancet Neurology.
[36] J. Arpa,et al. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases , 2013, BMC Neurology.
[37] L. Hickson,et al. Severe Hyponatremia as the Initial Sign Preceding Guillain-Barré Syndrome, an Acute Inflammatory Demyelinating Polyneuropathy: A Case Report , 2013, Case reports in neurological medicine.
[38] A. Kaplan,et al. Therapeutic plasma exchange: complications and management. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.